583₹ Health Care stock : Healthcare Global Enterprises Ltd, which operates under the “HCG” cancer care brand, saw its shares close lower in the latest trading session. The stock ended at ₹583, down nearly 2% from the previous close. At this level, the company’s market capitalisation stands at around ₹8,200 crore.
The Bengaluru-based company focuses mainly on oncology services and runs one of the largest private cancer care networks in India in terms of AERB-licensed centres. Apart from cancer treatment, it also operates fertility clinics under the “Milann” brand.
Brokerage Target Indicates Upside
Brokerage firm Prabhudas Lilladhar has given the stock a ‘Buy’ rating with a target price of ₹850 per share. Compared to the recent closing price, this implies a potential upside of around 45%.
The brokerage’s view appears to be based on expected improvement in operational performance and continued demand for specialised healthcare services, especially in oncology. Cancer treatment remains a high-entry-barrier segment due to infrastructure requirements and regulatory approvals, which limits competition to some extent.
Business Overview
Healthcare Global Enterprises has expanded gradually across multiple cities, focusing on tertiary cancer care. Oncology services typically involve advanced diagnostics, radiation therapy, chemotherapy, and surgical oncology — areas that require significant capital investment and medical expertise.
The fertility segment, though smaller compared to oncology, provides diversification and adds to the overall revenue base.
What Investors May Watch
While long-term demand for cancer care in India is structurally strong due to rising diagnosis rates and improving awareness, investors may keep an eye on:
- Occupancy levels at centres
- Expansion costs
- Debt levels
- Margin performance
Healthcare companies often require continuous investment in technology and infrastructure, which can affect short-term profitability.
For now, the stock has seen some recent volatility, but analyst coverage suggests confidence in the company’s long-term positioning.
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making investment decisions.